DXCM CLASS ACTION LAWSUIT: A Securities Fraud Class Action has been filed against DexCom, Inc. – Investors are Notified to Contact BFA Law to Potentially Recover Investment Losses

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. and its senior executives for securities fraud following significant stock declines attributed to potential violations of federal securities laws [1][2]. Company Overview - DexCom manufactures continuous glucose monitoring (CGM) systems, including the Dexcom G6 and G7, which were marketed as highly accurate devices [3]. Allegations - The lawsuit alleges that DexCom made unauthorized design changes to the G6 and G7, compromising their accuracy and exposing customers to serious health risks while prioritizing cost reduction over safety [4]. Stock Performance - DexCom's stock experienced notable declines due to revelations about product quality issues: - On March 7, 2025, the stock fell by $7.12 per share (over 9%) following an FDA warning letter regarding manufacturing concerns [5]. - After the FDA's public disclosure on March 25, 2025, the stock dropped another $3.19 per share (over 4%) [6]. - A report published on September 18, 2025, indicated severe safety issues, leading to a nearly 12% decline of $8.99 per share over two trading days [7].